Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories reports company news centered on veterinary diagnostics, software and animal-health testing. Recurring updates cover CAG Diagnostics recurring revenue, reference laboratory services, in-clinic analyzers, premium instrument placements and financial guidance tied to veterinary practice demand in the U.S. and international regions.
Company announcements also describe product innovation across pet healthcare, including IDEXX Cancer Dx testing, IDEXX inVue Dx, digital imaging systems such as Vue DR50 Plus, Web PACS software and connected workflow tools for veterinary practices. Other recurring topics include investor conference participation, governance and leadership updates, and products that support milk and water safety and livestock health.
IDEXX (NASDAQ:IDXX) expanded its Fecal Dx antigen testing platform to detect taeniid tapeworm, including Taenia and Echinococcus species. The platform is reported to identify up to twice as many intestinal parasite infections earlier than fecal flotation alone and now covers seven key parasite groups.
More than 50 million Fecal Dx tests have been run worldwide since 2012. Beginning in late June, IDEXX Reference Laboratories panels in the United States and Canada will automatically include taeniid tapeworm detection at no additional cost.
IDEXX Laboratories (NASDAQ: IDXX) will integrate the IDEXX SDMA Test into Catalyst CLIPs, adding kidney function evaluation to the most common in-clinic chemistry profiles. Starting June in the U.S. and Canada, veterinarians gain broader access to SDMA-based renal assessment with seamless workflow and VetConnect PLUS integration.
Supported by peer-reviewed evidence and IRIS recognition, IDEXX has run about 119 million SDMA tests globally since 2015, highlighting its role in earlier detection of chronic kidney disease in dogs and cats.
MindWalk Holdings (NASDAQ: HYFT) reported that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs now in active Phase 1–3 clinical trials across oncology, immunology, neurology, and infectious disease.
The company highlighted its HYFT® and LensAI™ biological intelligence infrastructure, built on a Knowledge Graph indexing 660 million biological patterns and 25 billion relationships, and a record of 400+ peer-reviewed publications and patents supporting collaborations with firms such as Annexon, argenx, Xencor, Cullinan Oncology, and others.
IDEXX Laboratories (NASDAQ: IDXX) announced CEO Mike Erickson will join a fireside chat at the Stifel Jaws & Paws Conference on May 27, 2026, from 10:55–11:25 am (ET), with a live and archived webcast.
The company will also host its 2026 Investor Day on August 13, 2026, 8:00 am–12:00 pm (ET), at its Westbrook, Maine headquarters, with a webcast and advance registration required for in-person institutional investors and analysts.
IDEXX Laboratories (NASDAQ: IDXX) reported Q1 2026 revenue of $1,141M, up 14% reported and 11% organic. Q1 EPS was $3.47, up 17% reported and 15% comparable. Company raised 2026 revenue guidance to $4,675M–$4,760M and EPS to $14.45–$14.90, citing stronger CAG Diagnostics recurring revenue and updated FX assumptions.
IDEXX Laboratories (NASDAQ: IDXX) will release its 2026 first quarter financial results on Tuesday, May 5, 2026, before the market opens.
An analyst conference call begins at 8:30 a.m. ET with a live webcast, prepared remarks transcript, and a Q1 2026 Earnings Snapshot available at www.idexx.com/investors.
An archived webcast will be posted after 1:00 p.m. ET on May 5 and remain available for one year. The live call is reachable by phone at 1-800-330-6730 or 1-213-279-1575 using passcode 492760.
IDEXX (NASDAQ: IDXX) announced UK availability of the IDEXX Cancer Dx Panel starting April 1, 2026, with lymphoma screening for at-risk dogs. Veterinarian pricing starts at £22.50 and results return in 3–5 business days. The blood test reports 79% sensitivity and 99% specificity and can detect a lymphoma signal up to eight months before clinical signs.
The panel integrates with wellness and sick-pet workflows, includes consult access to IDEXX medical specialists, and is available via IDEXX Reference Laboratories in the UK.
IDEXX Laboratories (NASDAQ: IDXX) will participate in two investor conferences in late February and early March 2026. A fireside chat with Mike Lane and Andrew Emerson is scheduled for Feb 26, 9:55–10:30 AM ET at the virtual BofA Securities Animal Health Summit. Jay Mazelsky will present on Mar 2, 9:15–9:45 AM ET at the Raymond James Institutional Investors Conference. Live webcasts and archived editions will be available through the company's investor website at www.idexx.com/investors.
IDEXX Laboratories (NASDAQ: IDXX) reported strong Q4 2025 results with revenue of $1,091M (+14% reported, +12% organic) and EPS of $3.08 (+18% reported, +17% comparable). Full-year revenue was $4,304M (+10%) and EPS $13.08 (+23% reported). The company recorded record instrument placements (including >1,900 IDEXX inVue Dx) and expanded margins; 2026 guidance targets revenue of $4,632M–$4,720M and EPS of $14.29–$14.80.
IDEXX (NASDAQ: IDXX) launched the ImageVue DR50 Plus digital imaging system on January 15, 2026, a connected veterinary radiography solution offering AI-powered imaging and integrated workflows. The system claims up to 25% lower radiation versus IDEXX’s prior DR50 and up to 60% lower radiation versus other veterinary systems, plus a new 17" x 17" panel option. Features include automated image optimization, irradiated side sampling to reduce retakes, IDEXX Web PACS integration, AI hanging protocols and vertebral heart scores, direct Telemedicine submission to 160+ board-certified specialists, and a claimed >45% reduction in clicks to submit cases. Available in the United States and Canada.